drugset / Trial / NCT05848635

Hydromorphone for Perioperative Analgesia in Lung Tumor Ablation Parallel Controlled

NCT05848635

Phase 4 Unknown 88 enrolled Qianfoshan Hospital
RandomizedParallel-groupDouble-blindTreatment

Summary

This randomized, parallel controlled, single blind trial is designed to evaluate the efficacy and safety of hydromorphone versus morphine for perioperative analgesia in lung tumor ablation.

Timeline

Start
2023-05-01
Primary completion
2024-05-01
Completion
2024-05-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Hydromorphone Other / unclassified 2 mg Subcutaneous
Comparator Morphine Other / unclassified 10 mg Subcutaneous

Indications